

30 August 2019

Early Notification and Brand Change

Chloramphenicol Eye Oint 1%

As advised via PHARMAC Tender Results of **30 August 2019** there is to be a change in the listing and future sole supply of Chloramphenicol.

New listing from 1 December 2019

Chloramphenicol-Deva Eye Oint 1% 5 gm OP

Pharmacode 2576902 Schedule price \$1.55

Incumbent brand

Chlorsig Eye Oint 1% 4 gm OP

Pharmacode 335150 Schedule price \$2.48

HSS (Hospital Supply Status) & CSS (Community Supply Status) commences 1 May 2020.

Brand switch fee not advised in Tender notification.

As of the date of this notification ProPharma / PWR cannot accept **Chlorsig Eye Oint 1%** for credit under any circumstances.

From **1 December 2019** community pharmacies dispensing **Chloramphenicol Eye Oint 1% 4 gm** will need to support patients changing to the new brand and manage stock during the transition.

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.

Benefit of staying with incumbent while stock remains available are minimal, but every cent counts:-

Chlorsig : - Dispensing 1 OP. Therefore 1 @ \$2.48 x 3% = \$0.0744 plus \$0.256 (pack fee) giving you **\$0.3304**

Chloramphenicol : - Dispensing 1 OP. Therefore 1 @ \$1.55 x 3% = \$0.0465 plus \$0.256 (pack fee) giving you **\$0.3025**

You **MUST** manage your stock to avoid being caught with stock at the time sole supply commences **1 May 2020**. Failure to do so may prove very costly.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.

ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply **1 May 2020** we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

Early Notification and Brand Change

Clopidogrel Tab 75 mg

As advised via PHARMAC Tender Results of **30 April 2019** there is to be a change in the listing and future sole supply of Clopidogrel tablets 75 mg

New listing from 1 December 2019

Clopidogrel Multichem Tab 75 mg 84
Pharmacode 2567997 Schedule price \$4.60

Incumbent brand

Clopid-Arrow Tab 75 mg 84
Pharmacode 2443201 Schedule price \$5.44

HSS (Hospital Supply Status) & **CSS** (Community Supply Status) commences **1 May 2020**.

Brand switch fee for Community Pharmacy not advised.

As of the date of this notification ProPharma / PWR cannot accept **Clopidogrel-Arrow** for credit under any circumstances.

From **1 December 2019** community pharmacies dispensing **Clopidogrel tablets 75 mg** will need to support patients changing to the new brand and manage stock during the transition.

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.

Benefit of staying with incumbent while stock remains available are minimal, but every cent counts:-

Clopid-Arrow : - Average dispensing is 84. Therefore $1 \times @ \$5.44 \times 3\% = \0.1632 plus \$0.253 (pack fee) giving you **\$0.4162**

Compared to $\$4.60 \times 3\% = \0.1380 plus \$0.253 (pack fee) giving you **\$0.3910**

You **MUST** manage your stock to avoid being caught with stock at the time sole supply commences **1 May 2020**. Failure to do so may prove very costly.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.

ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply **1 May 2020** we

need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

Early Notification and Brand Change

Droperidol Injection

As advised via PHARMAC Tender Results of **31 May 2019** there is to be a change in the listing and future sole supply of Droperidol Injection.

New listing from 1 December 2019 HML only

Droleptan Inj 2.5 mg per ml, 1 ml ampoule; 10 ampoule pack
Pharmacode 727253 Schedule price \$30.95

Incumbent brand

Droperidol Panpharma Inj 2.5 mg per ml, 1 ml ampoule; 10 ampoule pack
Pharmacode 2527138 Schedule price \$35.00

HSS (Hospital Supply Status) commences 1 May 2020.

As of the date of this notification ProPharma / PWR cannot accept **Droperidol Panpharma Inj** for credit under any circumstances.

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.

You **MUST** manage your stock to avoid being caught with stock at the time sole supply commences **1 May 2020**. Failure to do so may prove very costly.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.

ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply **1 May 2020** we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

Early Notification and Brand Change

REVISED

Temozolomide Capsules

As advised via PHARMAC Tender Results of **29 March 2019** there is to be a change in the listing and future sole supply of Temozolomide Capsules.

Please refer to our original notification of 29 March 2019 for original timings as all but 5 mg will now be listed from 1 October 2019 to ensure ongoing supply. ***(Only the listing date changes)***

New listing from 1 October 2019

Temaccord Caps 20 mg 5 capsule bottle pack

Pharmacode 2388251

Schedule price \$16.38

Temaccord Caps 100 mg 5 capsule bottle pack

Pharmacode 2388243

Schedule price \$35.98

Temaccord Caps 140 mg 5 capsule bottle pack

Pharmacode 2566044

Schedule price \$50.12

Temaccord Caps 250 mg 5 capsule bottle pack

Pharmacode 2388235

Schedule price \$86.34

Incumbent brand and DELISTED 1 May 2020

Temozolomide Orion Caps 20 mg 5 capsule bottle pack

Pharmacode 2505959 Schedule price \$18.30

Temozolomide-Apo Cap 20 mg 5 capsules per bottle pack

Pharmacode 2572311 Schedule price \$18.30

Temizole Caps 20 mg 5 capsule bottle pack S29

Pharmacode 2527170 Schedule price \$96.80

Temozolomide Orion Caps 100 mg 5 capsule bottle pack

Pharmacode 2505967 Schedule price \$40.20

Temozolomide-Apo Caps 100 mg 5 capsule bottle pack

Pharmacode 2572338 Schedule price \$40.20

Temozolomide Orion Caps 140 mg 5 capsule bottle pack

Pharmacode 2527162 Schedule price \$56.00

Temozolomide Orion Caps 250 mg 5 capsule bottle pack

Pharmacode 2505975 Schedule price \$96.80

Reference pricing will not apply.

HSS (Hospital Supply Status) & **CSS** (Community Supply Status) commences **1 May 2020**.

Brand Switch Fee not in notification.

As of the date of this notification ProPharma / PWR cannot accept **Temozolomide Orion (all strengths)** for credit under any circumstances.

From **1 October 2019** community pharmacies dispensing **Temozolomide Capsules** (other than 5 mg) will need to support patients changing to the new brand and manage stock during the transition.

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.

You **MUST** manage your stock to avoid being caught with stock at the time sole supply commences **1 May 2020**. Failure to do so may prove costly.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.

ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both products listed and fully funded until the commencement of the sole supply **1 May 2020** we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

Early Notification and Brand Change

Tranexamic Acid Tablet

As advised via PHARMAC Tender Results of **28 June 2019** there is to be a change in the listing and future sole supply of Tranexamic Acid Tablet.

New listing from 1 December 2019

Tranexamic Acid-Boucher Tab 500mg, 60 tablet blister pack
Pharmacode 2574020 Schedule price \$9.45

Incumbent brand

Cyklokapron Tab 500 mg, 100 tablet bottle pack
Pharmacode 461962 Schedule price \$20.67

HSS (Hospital Supply Status) & Community Sole Supply commences 1 May 2020.

Brand Switch Fee not notified at time of notification.

As of the date of this notification ProPharma / PWR cannot accept **Cyklokapron Tablets** for credit under any circumstances.

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.

You **MUST** manage your stock to avoid being caught with stock at the time sole supply commences **1 May 2020**. Failure to do so may prove very costly.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.

ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply **1 May 2020** we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.